These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11915520)

  • 1. [Pharmacological and clinical properties of levocabastine hydrochloride (eye drop and nasal spray), a selective H1 antagonist].
    Akiyoshi M; Shigeoka T; Torii S; Maki E; Enomoto S; Takahashi H; Hirano F
    Nihon Yakurigaku Zasshi; 2002 Mar; 119(3):175-84. PubMed ID: 11915520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis.
    Dechant KL; Goa KL
    Drugs; 1991 Feb; 41(2):202-24. PubMed ID: 1709851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
    Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
    Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effect of levocabastine on experimental allergic conjunctivitis in guinea pigs.
    Kamei C; Izushi K; Tasaka K
    J Pharmacobiodyn; 1991 Aug; 14(8):467-73. PubMed ID: 1723098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levocabastine: a new topical approach for the treatment of paediatric allergic rhinoconjunctivitis.
    Janssens MM
    Rhinol Suppl; 1992 Sep; 13():39-49. PubMed ID: 1358140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis.
    Janssens MM; Vanden Bussche G
    Clin Exp Allergy; 1991 May; 21 Suppl 2():29-36. PubMed ID: 1680536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis.
    Noble S; McTavish D
    Drugs; 1995 Dec; 50(6):1032-49. PubMed ID: 8612470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiallergic profile of the novel H1-antihistaminic compound levocabastine.
    Tasaka K; Kamei C; Akagi M; Mio M; Shirasaka T; Chokki M
    Arzneimittelforschung; 1993 Dec; 43(12):1331-7. PubMed ID: 7511378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of topical levocabastine on nasal response to allergen challenge and nasal hyperreactivity in perennial rhinitis.
    de Graaf-in 't Veld T; Garrelds IM; van Toorenenbergen AW; Mulder PG; Gerth van Wijk R; Boegheim JP
    Ann Allergy Asthma Immunol; 1995 Sep; 75(3):261-6. PubMed ID: 7552929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective effect of levocabastine on histamine receptor and histamine release from human leukocytes and guinea pig isolated tissue.
    Garrelds IM; de Graaf-in't Veld T; van Toorenenbergen AW; van Wijk RG; Boegheim JP; Saxena PR; Zijlstra FJ
    Ann Allergy Asthma Immunol; 1996 Apr; 76(4):327-34. PubMed ID: 8612114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical levocabastine, a selective H1 antagonist, in seasonal allergic rhinoconjunctivitis.
    Bende M; Pipkorn U
    Allergy; 1987 Oct; 42(7):512-5. PubMed ID: 2891316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The early efficacy of topical levocabastine in patients with allergic conjunctivitis.
    Fujishima H; Fukagawa K; Takano Y; Okamoto S; Nakagawa Y; Uchio E; Yokoi N; Fukushima A; Takamura E
    Allergol Int; 2006 Sep; 55(3):301-3. PubMed ID: 17075271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of levocabastine on allergen-induced increase of nasal reactivity to histamine and cell influx.
    Pazdrak K; Górski P; Ruta U
    Allergy; 1993 Nov; 48(8):598-601. PubMed ID: 7906926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.
    Ohmori K; Hayashi K; Kaise T; Ohshima E; Kobayashi S; Yamazaki T; Mukouyama A
    Jpn J Pharmacol; 2002 Apr; 88(4):379-97. PubMed ID: 12046981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a new selective H1 receptor antagonist (levocabastine) in a nasal and conjunctival provocation test.
    Pécoud A; Zuber P; Kolly M
    Int Arch Allergy Appl Immunol; 1987; 82(3-4):541-3. PubMed ID: 2883132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Second generation topical antihistaminics].
    Pietrzkowicz M; Grzelewska-Rzymowska I
    Pol Merkur Lekarski; 1999 May; 6(35):277-80. PubMed ID: 10437402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New trends in the treatment of allergic conjunctivitis.
    Parys W; Blockhuys S; Janssens M
    Doc Ophthalmol; 1992; 82(4):353-60. PubMed ID: 1363981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of histamine-induced conjunctivitis to the assessment of a topical antihistamine, levocabastine.
    Feinberg G; Stokes TC
    Int Arch Allergy Appl Immunol; 1987; 82(3-4):537-8. PubMed ID: 2883131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical levocabastine for the treatment of perennial allergic rhinitis.
    Elwany S; Bassiouny M
    J Laryngol Otol; 1997 Oct; 111(10):935-40. PubMed ID: 9425481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levocabastine: pharmacological profile of a highly effective inhibitor of allergic reactions.
    Awouters F; Niemegeers CJ; Jansen T; Megens AA; Janssen PA
    Agents Actions; 1992 Jan; 35(1-2):12-8. PubMed ID: 1354927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.